Cardiex Receives TGA Approval for CONNEQT Pulse Device

Cardiex Receives TGA Approval for CONNEQT Pulse Device

Cardiex Limited (CDX:AU) has announced Cardiex Receives TGA Approval for CONNEQT Pulse Device

Download the PDF here.

Cardiex Limited

Cardiex Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Biomarker technologies and digital solutions to address the world’s largest health disorders.

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers

Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.

Resolutions proposed and approved at the AGM were:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
BetterInvesting Magazine Update on Stride Inc.  and Amgen Inc.

BetterInvesting Magazine Update on Stride Inc. and Amgen Inc.

Stride Inc.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Stride Inc. (NYSE:LRN) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Stride's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., here .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Man holds hand to head as fragments break off representing Alzheimer's disease.

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.

Keep reading...Show less
Cardiex Limited

Cardiex Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×